^
Association details:
| Biomarker: | DDR |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD-L1 inhibitor + CTLA4 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MA13.03 - DNA Damage Response Gene Alterations and their Association with Tumor Mutation Burden and Response to Immunotherapy in NSCLC and SCLC
Published date:
01/12/2021
Excerpt:
Compared to the WT group, median progression-free survival (PFS) in the DDR alterations group was dramatically longer (23 vs 3.7 months, HR: 0.32 [95%CI: 0.19-0.57], P < 0.001)...DDR alterations correlate with improved clinical outcomes in NSCLC patients treated with a combination of PD-1 and CTLA-4 blockade.
